ClinVar Miner

Submissions for variant NM_004369.3(COL6A3):c.6354+1G>A (rs886042883)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
EGL Genetic Diagnostics,Eurofins Clinical Diagnostics RCV000578834 SCV000338903 pathogenic not provided 2018-01-08 criteria provided, single submitter clinical testing
Invitae RCV000319175 SCV000657374 pathogenic Bethlem myopathy 1 2019-02-28 criteria provided, single submitter clinical testing This sequence change affects a donor splice site in intron 19 of the COL6A3 gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. This variant is not present in population databases (ExAC no frequency). This variant has been observed in individuals affected with Bethlem myopathy (PMID: 28688748, Invitae). ClinVar contains an entry for this variant (Variation ID: 285748). Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in COL6A3 are known to cause autosomal recessive COL6A3-related disorders (PMID: 20976770). However, splice site variants in COL6A3 have also been reported to cause autosomal dominant COL6A3-related disorders (PMID: 20976770, 15563506, 18366090). For these reasons, this variant has been classified as Pathogenic.
GeneDx RCV000578834 SCV000681255 pathogenic not provided 2017-12-12 criteria provided, single submitter clinical testing The c.6354+1G>A variant in the COL6A3 gene has not been reported previously as a pathogenic variant nor as a benign variant, to our knowledge. This splice site variant destroys the canonical splice donor site in intron 19. It is predicted to cause abnormal gene splicing, either leading to an abnormal message that is subject to nonsense-mediated mRNA decay, or to an abnormal protein product if the message is used for protein translation. The c.6354+1G>A variant is not observed in large population cohorts (Lek et al., 2016). We interpret c.6354+1G>A as a pathogenic variant.
Ambry Genetics RCV000622451 SCV000742627 likely pathogenic Inborn genetic diseases 2017-07-07 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: UNCERTAIN: Alteration(s) of Uncertain Clinical Significance Detected
GenomeConnect, ClinGen RCV001249572 SCV001423541 not provided Bethlem myopathy 1; Ullrich congenital muscular dystrophy 1 no assertion provided phenotyping only Variant interpretted as Pathogenic and reported on 12-13-2017 by Lab or GTR ID 26957. GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.